

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/024472 A2

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number: **PCT/CA02/01345**

(22) International Filing Date: 30 August 2002 (30.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/322,514 14 September 2001 (14.09.2001) US
60/386,404 7 June 2002 (07.06.2002) US

(71) Applicant (for all designated States except US): **STEM CELL THERAPEUTICS INC.** [CA/CA]; Suite 240, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEISS, Samuel** [CA/CA]; 4540 Chapel Road, N.W., Calgary, Alberta T2L 1A6 (CA). **SHINGO, Tetsuro** [JP/JP]; 3-9-33 #103, Aoe, Okayama 700-0941 (JP).

(74) Agent: **TORYS LLP**; Suite 3000, 79 Wellington St. W., Box 270, TD Centre, Toronto, Ontario M5K 1N2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent

[Continued on next page]

(54) Title: **PROLACTIN INDUCED INCREASE IN NEUTRAL STEM CELL NUMBERS**



(57) Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced *in vivo* to obtain more neural stem cells *in situ*, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced *in vitro* to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.

WO 03/024472 A2



(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent

(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PROLACTIN INDUCED INCREASE IN NEURAL STEM CELL NUMBERS**5 FIELD OF THE INVENTION**

The present invention relates to methods of increasing neural stem cell numbers, neurogenesis or new olfactory neuron numbers by using prolactin, as well as methods for treating or ameliorating neurodegenerative diseases or conditions.

10

REFERENCES

U.S. Patent Application Publication No. 2002 0098178 A1.

U.S. Patent No. 5,023,252.

U.S. Patent No. 5,128,242.

15 U.S. Patent No. 5,198,542.

U.S. Patent No. 5,208,320.

U.S. Patent No. 5,268,164.

U.S. Patent No. 5,326,860.

U.S. Patent No. 5,506,107.

20 U.S. Patent No. 5,506,206.

U.S. Patent No. 5,527,527.

U.S. Patent No. 5,547,935.

U.S. Patent No. 5,614,184.

U.S. Patent No. 5,623,050.

25 U.S. Patent No. 5,686,416.

U.S. Patent No. 5,723,115.

U.S. Patent No. 5,750,376.

U.S. Patent No. 5,773,569.

U.S. Patent No. 5,801,147.

30 U.S. Patent No. 5,833,988.

U.S. Patent No. 5,837,460.

- U.S. Patent No. 5,851,832.
U.S. Patent No. 5,885,574.
U.S. Patent No. 5,955,346.
U.S. Patent No. 5,977,307.
5 U.S. Patent No. 5,980,885.
U.S. Patent No. 6,015,555.
U.S. Patent No. 6,048,971.
U.S. Patent No. 6,191,106.
U.S. Patent No. 6,242,563.
10 U.S. Patent No. 6,329,508.
U.S. Patent No. 6,333,031.
U.S. Patent No. 6,413,952.
U.S. Patent No. 6,429,186.
WO 96 40231.
15 WO 97 48729.
Bernichtein, S., et al. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist. *Endocrinology* 142(9):3950-3963 (2001).

DeVito, W.J., et al., "Prolactin induced expression of interleukin-1 alpha, tumor necrosis
20 factor-alpha, and transforming growth factor-alpha in cultured astrocytes", *J. Cell Biochem.*
57:290-298 (1995).

Fernandez-Pol, J.A. Epidermal growth factor receptor of A431 cells. Characterization of a
monoclonal anti-receptor antibody noncompetitive agonist of epidermal growth factor action.
25 *J. Biol. Chem.* 260(8):5003-5011 (1985).

Freeman, M.E., et al., "Prolactin: structure, function and regulation of secretion", *Physiol.*
Rev. 80:1523-1631 (2000).

30 Johnson, D.L., et al. Erythropoietin mimetic peptides and the future. *Nephrol. Dial.*
Transplant. 15(9):1274-1277 (2000).

Kaushansky, K. Hematopoietic growth factor mimetics. *Ann. N.Y. Acad. Sci.* 938:131-138 (2001).

5 Kolb, B., et al. Nerve growth factor treatment prevents dendritic atrophy and promotes recovery of function after cortical injury. *Neuroscience* 76(4):1139-1151 (1997).

Lim, D.A., et al., "Noggin antagonizes BMP signaling to create a niche for adult neurogenesis", *Neuron* 28: 713-726 (2000).

10

Livnah, O., et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. *Science* 273(5274):464-471 (1996).

15

Mode, A., et al. The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. *Endocrinology* 137(2):447-454 (1996).

20

Moro, O., et al. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. *J. Biol. Chem.* 272(2):966-70 (1997).

Rocheffort, C., et al. Enriched odor exposure increases the number of newborn neurons in the adult olfactory bulb and improves odor memory. *J. Neurosci.* 22(7):2679-2689 (2002).

25

Shingo, T., et al. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. *J. Neurosci.* 21(24):9733-9743 (2001).

30

Wrighton, N.C., et al. Small peptides as potent mimetics of the protein hormone erythropoietin. *Science* 273(5274):458-464 (1996).

All of the publications, patents and patent applications cited above or elsewhere in this application are herein incorporated by reference in their entirety to the same extent as if the disclosure of each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.

5

BACKGROUND OF THE INVENTION

In recent years, neurodegenerative disease has become an important concern due to the expanding elderly population which is at greatest risk for these disorders.

10 Neurodegenerative diseases include the diseases which have been linked to the degeneration of neural cells in particular locations of the central nervous system (CNS), leading to the inability of these cells to carry out their intended function. These diseases include Alzheimer's Disease, Multiple Sclerosis (MS), Huntington's Disease, Amyotrophic Lateral Sclerosis, and Parkinson's Disease. In addition, probably the largest area of CNS dysfunction
15 (with respect to the number of affected people) is not characterized by a loss of neural cells but rather by abnormal functioning of existing neural cells. This may be due to inappropriate firing of neurons, or the abnormal synthesis, release, and processing of neurotransmitters. These dysfunctions may be the result of well studied and characterized disorders such as depression and epilepsy, or less understood disorders such as neurosis and psychosis.
20 Moreover, brain injuries often result in the loss of neural cells, the inappropriate functioning of the affected brain region, and subsequent behavior abnormalities.

Consequently, it is desirable to supply neural cells to the brain to compensate for degenerate or lost neurons in order to treat neurodegenerative diseases or conditions. One
25 approach to this end is to transplant neural cells into the brain of the patient. This approach requires a source of large amounts of neural cells, preferably from the same individual or a closely related individual such that host-versus-graft or graft-versus-host rejections can be minimized. As it is not practical to remove a large amount of neurons or glial cells from one person to transplant to another, a method to culture large quantity of neural cells is necessary
30 for the success of this approach.

Another approach is to induce the production of neural cells *in situ* to compensate for the lost or degenerate cells. This approach requires extensive knowledge about whether it is possible to produce neural cells in brains, particularly adult brains, and how.

5 The development of techniques for the isolation and *in vitro* culture of multipotent neural stem cells (for example, see U.S. Patent Nos. 5,750,376; 5,980,885; 5,851,832) significantly increased the outlook for both approaches. It was discovered that fetal brains can be used to isolate and culture multipotent neural stem cells *in vitro*. Moreover, in contrast to the long time belief that adult brain cells are not capable of replicating or
10 regenerating brain cells, it was found that neural stem cells may also be isolated from brains of adult mammals. These stem cells, either from fetal or adult brains, are capable of self-replicating. The progeny cells can again proliferate or differentiate into any cell in the neural cell lineage, including neurons, astrocytes and oligodendrocytes. Therefore, these findings not only provide a source of neural cells which can be used in transplantations, but also
15 demonstrate the presence of multipotent neural stem cells in adult brain and the possibility of producing neurons or glial cells from these stem cells *in situ*.

It is therefore desirable to develop methods of efficiently producing neural stem cells for two purposes: to obtain more stem cells and hence neural cells which can be used in
20 transplantation therapies, and to identify methods which can be used to produce more stem cells *in situ*.

SUMMARY OF THE INVENTION

25 The present invention provides a method of increasing neural stem cell numbers by using prolactin. The method can be practiced *in vivo* to obtain more neural stem cells *in situ*, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced *in vitro* to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation
30 treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.

Accordingly, one aspect of the present invention provides a method of increasing neural stem cell number, comprising providing an effective amount of a prolactin to at least one neural stem cell under conditions which result in an increase in the number of neural stem cells. The neural stem cell may be located in the brain of a mammal, in particular in the subventricular zone of the brain of the mammal. Preferably, the prolactin is administered to the ventricle of the brain. Although mammals of all ages can be subjected to this method, it is preferable that the mammal is not an embryo. More preferably, the mammal is an adult.

The mammal may suffer from or be suspected of having a neurodegenerative disease or condition. The disease or condition may be a brain injury, such as stroke or an injury caused by a brain surgery. The disease or condition may be aging, which is associated with a significant reduction in the number of neural stem cells. The disease or condition can also be a neurodegenerative disease, particularly Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, or Parkinson's disease.

Alternatively, the neural stem cell may be in a culture *in vitro*.

Whether the prolactin is used *in vivo* or *in vitro*, other factors may be applied in combination with the prolactin, such as erythropoietin, cyclic AMP, pituitary adenylate cyclase activating polypeptide (PACAP), serotonin, bone morphogenetic protein (BMP), epidermal growth factor (EGF), transforming growth factor alpha (TGF), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and/or ciliary neurotrophic factor (CNTF). The prolactin may be any prolactin analog or variant which is capable of inducing an increase in the stem cell number. Preferably, the prolactin is a mammalian prolactin, most preferably a human prolactin.

Another aspect of the present invention provides a method of treating or ameliorating a neurodegenerative disease or condition in a mammal, comprising providing an effective amount of a prolactin to the brain of the mammal. The disease or condition may be a brain injury, such as stroke or an injury caused by a brain surgery. The disease or condition may

be aging, which is associated with a significant reduction in the number of neural stem cells. The disease or condition can also be a neurodegenerative disease, particularly Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, or Parkinson's disease.

5

The mammal can optionally receive a transplantation of neural stem cells and/or neural stem cell progeny. The transplantation may take place before, after, or at the same time the mammal receives the prolactin. Preferably, the mammal receives the transplantation prior to or concurrently with the prolactin.

10

The mammal can optionally receive at least one additional factor, such as erythropoietin, cyclic AMP, pituitary adenylate cyclase activating polypeptide (PACAP), serotonin, bone morphogenetic protein (BMP), epidermal growth factor (EGF), transforming growth factor alpha (TGF), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and/or ciliary neurotrophic factor (CNTF).

15

The prolactin and/or the additional factor can be provided by any method established in the art. For example, they can be administered intravascularly, intrathecally, intravenously, intramuscularly, subcutaneously, intraperitoneally, topically, orally, rectally, vaginally, nasally, by inhalation or into the brain. The administration is preferably performed systemically, particularly by subcutaneous administration. The prolactin or additional factor can also be provided by administering to the mammal an effective amount of an agent that can increase the amount of endogenous prolactin or the additional factor in the mammal. For example, the level of prolactin in an animal can be increased by using prolactin releasing peptide.

20

25

When prolactin or any additional factor is not directly delivered into the brain, a blood brain barrier permeabilizer can be optionally included to facilitate entry into the brain. Blood brain barrier permeabilizers are known in the art and include, by way of example, bradykinin and the bradykinin agonists described in U.S. Patent Nos. 5,686,416; 5,506,206 and 5,268,164 (such as NH₂-arginine-proline-hydroxyproline-glycine-

30

thienylalanine-serine-proline-4-Me-tyrosine-(CH₂NH)- arginine-COOH). Alternatively, the factors can be conjugated to the transferrin receptor antibodies as described in U.S. Patent Nos. 6,329,508; 6,015,555; 5,833,988 or 5,527,527. The factors can also be delivered as a fusion protein comprising the factor and a ligand that is reactive with a brain capillary endothelial cell receptor, such as the transferrin receptor (see, *e.g.*, U.S. Patent No. 5,977,307).

Another aspect of the present invention provides a method of enhancing neuron formation from neural stem cells, comprising providing a prolactin to at least one neural stem cell under conditions that result in enhanced neuron formation from said neural stem cell. Further provided is a method of increasing new neuron formation in the olfactory bulb of a mammal, comprising providing an effective amount of a prolactin to the mammal. Compositions and pharmaceutical compositions comprising a prolactin and at least one additional factor are also provided.

Further aspects of the present invention provide compositions and pharmaceutical compositions useful in the present invention, comprising a prolactin and optionally an additional factor. The compositions or pharmaceutical compositions preferably comprise prolactin and erythropoietin, prolactin and EGF, or prolactin and PACAP.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Time course for SVZ proliferation and NSC numbers in pregnant female mice.

*significantly different from aged matched virgins, $p < 0.05$.

** $p < 0.01$.

N.D.: not determined.

Figure 2. The effects of prolactin infusion. PRL: prolactin; VEH: vehicle; PRP: PRL-releasing peptide; 2W: 2 weeks; 4W: 4 weeks. * $p < 0.05$.

(A) Prolactin infusion increased BrdU-labeled cells in the forebrain SVZ via both subcutaneous and intracerebroventricular routes.

(B) Prolactin infusion increased new periglomerular neurons in the olfactory bulb two weeks (2W) and 4 weeks (4W) after BrdU injections.

(C) Prolactin infusion increased BrdU-labeled cells in the forebrain SVZ in both male and female animals. In non-ovariectomized females and in males, intracerebroventricular
5 infusions of prolactin (PRL) and PRL-releasing peptide (PRP) stimulated SVZ proliferation.

Figure 3. Prolactin potentiated the effect of EGF to increase neurospheres. In the presence of EGF, prolactin (PRL) induced a dose-dependent increase in the proliferation of neural stem cells (NSCs), and in their self-renewal. * $p < 0.05$. ** $p < 0.01$.

Figure 4. Prolactin doubled the number of neurons produced by neural stem cells. Neurospheres grown in the presence of EGF alone or EGF plus 30 nM prolactin (PRL) were allowed to differentiate in basal media, and the percentage of neurons in neurospheres grown in EGF plus prolactin was twice as much as that in neurospheres grown in EGF alone.
15 * $p < 0.05$.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of increasing neural stem cell numbers by
20 using prolactin. The method can be practiced *in vivo* to obtain more neural stem cells *in situ*, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced *in vitro* to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative
25 diseases or conditions.

Prior to describing the invention in further detail, the terms used in this application are defined as follows unless otherwise indicated.

Definitions

5 A "neural stem cell" is a stem cell in the neural cell lineage. A stem cell is a cell which is capable of reproducing itself. In other words, daughter cells which result from stem cell divisions include stem cells. The neural stem cells are capable of ultimately differentiating into all the cell types in the neural cell lineage, including neurons, astrocytes and oligodendrocytes (astrocytes and oligodendrocytes are collectively called glia or glial cells). Thus, the neural stem cells referred to herein are multipotent neural stem cells.

10 A "neurosphere" is a group of cells derived from a single neural stem cell as the result of clonal expansion. A "primary neurosphere" refers to the neurospheres generated by plating as primary cultures brain tissue which contains neural stem cells. The method for culturing neural stem cells to form neurospheres has been described in, for example, U.S. Pat. No. 5,750,376. A "secondary neurosphere" refers to the neurospheres generated by
15 dissociating primary neurospheres and allowing the individual dissociated cells to form neurospheres again.

A polypeptide which shares "substantial sequence similarity" with a native factor is at least about 30% identical with the native factor at the amino acid level. The polypeptide is
20 preferably at least about 40%, more preferably at least about 60%, yet more preferably at least about 70%, and most preferably at least about 80% identical with the native factor at the amino acid level.

The phrase "percent identity" or "% identity" of an analog or variant with a native
25 factor refers to the percentage of amino acid sequence in the native factor which are also found in the analog or variant when the two sequences are aligned. Percent identity can be determined by any methods or algorithms established in the art, such as LALIGN or BLAST.

A polypeptide possesses a "biological activity" of a native factor if it is capable of
30 binding to the receptor for the native factor or being recognized by a polyclonal antibody

raised against the native factor. Preferably, the polypeptide is capable of specifically binding to the receptor for the native factor in a receptor binding assay.

5 A "functional agonist" of a native factor is a compound that binds to and activates the receptor of the native factor, although it does not necessarily share a substantial sequence similarity with the native factor.

10 A "prolactin" is a polypeptide which (1) shares substantial sequence similarity with a native mammalian prolactin, preferably the native human prolactin; and (2) possesses a biological activity of the native mammalian prolactin. The native human prolactin is a 199-amino acid polypeptide synthesized mainly in the pituitary gland. Thus, the term "prolactin" encompasses prolactin analogs which are the deletional, insertional, or substitutional mutants of the native prolactin. Furthermore, the term "prolactin" encompasses the prolactins from other species and the naturally occurring variants thereof.

15 In addition, a "prolactin" may also be a functional agonist of a native mammalian prolactin receptor. For example, the functional agonist may be an activating amino acid sequence disclosed in U.S. Patent No. 6,333,031 for the prolactin receptor; a metal complexed receptor ligand with agonist activities for the prolactin receptor (U.S. Patent No. 6,413,952); G120RhGH, which is an analog of human growth hormone but acts as a prolactin agonist (Mode et al., 1996); or a ligand for the prolactin receptor as described in U.S. Patent
20 Nos. 5,506,107 and 5,837,460.

25 An "EGF" means a native EGF or any EGF analog or variant that shares a substantial amino acid sequence similarity with a native EGF, as well as at least one biological activity with the native EGF, such as binding to the EGF receptor. Particularly included as an EGF is the native EGF of any species, TGF, or recombinant modified EGF. Specific examples include, but are not limited to, the recombinant modified EGF having a deletion of the two C-terminal amino acids and a neutral amino acid substitution at position 51 (particularly EGF51gln51; U.S. Patent Application Publication No. 20020098178A1), the EGF mutein (EGF-X₁₆) in which the His residue at position 16 is replaced with a neutral or acidic amino
30 acid (U.S. Patent No. 6,191,106), the 52-amino acid deletion mutant of EGF which lacks the

amino terminal residue of the native EGF (EGF-D), the EGF deletion mutant in which the N-terminal residue as well as the two C-terminal residues (Arg-Leu) are deleted (EGF-B), the EGF-D in which the Met residue at position 21 is oxidized (EGF-C), the EGF-B in which the Met residue at position 21 is oxidized (EGF-A), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, amphiregulin, neuregulin, or a fusion protein comprising any of the above. Other useful EGF analogs or variants are described in U.S. Patent Application Publication No. 20020098178A1, and U.S. Patent Nos. 6,191,106 and 5,547,935.

In addition, an "EGF" may also be a functional agonist of a native mammalian EGF receptor. For example, the functional agonist may be an activating amino acid sequence disclosed in U.S. Patent No. 6,333,031 for the EGF receptor, or an antibody that has agonist activities for the EGF receptor (Fernandez-Pol, 1985 and U.S. Patent No. 5,723,115).

A "PACAP" means a native PACAP or any PACAP analog or variant that shares a substantial amino acid sequence similarity with a native PACAP, as well as at least one biological activity with the native PACAP, such as binding to the PACAP receptor. Useful PACAP analogs and variants include, without being limited to, the 38 amino acid and the 27 amino acid variants of PACAP (PACAP38 and PACAP27, respectively), and the analogs and variants disclosed in, *e.g.*, U.S. Patent Nos. 5,128,242; 5,198,542; 5,208,320; 5,326,860; 5,623,050; 5,801,147 and 6,242,563.

In addition, a "PACAP" may also be a functional agonist of a native mammalian PACAP receptor. For example, the functional agonist may be maxadilan, a polypeptide that acts as a specific agonist of the PACAP type-1 receptor (Moro et al., 1997).

An "erythropoietin (EPO)" means a native EPO or any EPO analog or variant that shares a substantial amino acid sequence similarity with a native EPO, as well as at least one biological activity with the native EPO, such as binding to the EPO receptor. Erythropoietin analogs and variants are disclosed, for example, in U.S. Patent Nos. 6,048,971 and 5,614,184.

In addition, an "EPO" may also be a functional agonist of a native mammalian EPO receptor. For example, the functional agonist may be EMP1 (EPO mimetic peptide 1,

Johnson et al., 2000); one of the short peptide mimetics of EPO as described in Wrighton et al., 1996 and U.S. Patent No. 5,773,569; any small molecular EPO mimetic as disclosed in Kaushansky, 2001; an antibody that activates the EPO receptor as described in U.S. Patent No. 5,885,574, WO 96/40231, WO 97/48729, Fernandez-Pol, 1985 or U.S. Patent No. 5,723,115; an activating amino acid sequence as disclosed in U.S. Patent No. 6,333,031 for the EPO receptor; a metal complexed receptor ligand with agonist activities for the EPO receptor (U.S. Patent No. 6,413,952), or a ligand for the EPO receptor as described in U.S. Patent Nos. 5,506,107 and 5,837,460.

10 A "prolactin-inducing agent" is a substance that, when given to an animal, is capable of increasing the amount of prolactin in the animal. For example, prolactin releasing peptide stimulates the secretion of prolactin.

 "Enhancing" the formation of a cell type means increasing the number of the cell type. Thus, a factor can be used to enhance neuron formation if the number of neurons in the presence of the factor is larger than the number of neurons absent the factor. The number of neurons in the absence of the factor may be zero or more.

 A "neurodegenerative disease or condition" is a disease or medical condition associated with neuron loss or dysfunction. Examples of neurodegenerative diseases or conditions include neurodegenerative diseases, brain injuries or CNS dysfunctions. Neurodegenerative diseases include, for example, Alzheimer's disease, multiple sclerosis (MS), macular degeneration, glaucoma, diabetic retinopathy, peripheral neuropathy, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease. Brain injuries include, for example, stroke (e.g., hemorrhagic stroke, focal ischemic stroke or global ischemic stroke) and traumatic brain injuries (e.g. injuries caused by a brain surgery or physical accidents). CNS dysfunctions include, for example, depression, epilepsy, neurosis and psychosis.

30 "Treating or ameliorating" means the reduction or complete removal of the symptoms of a disease or medical condition.

A mammal "suspected of having a neurodegenerative disease or condition" is a mammal which is not officially diagnosed with the neurodegenerative disease or condition but shows a symptom of the neurodegenerative disease or condition, is susceptible to the neurodegenerative disease or condition due to family history or genetic predisposition, or has previously had the neurodegenerative disease or condition and is subject to the risk of recurrence.

"Transplanting" a composition into a mammal refers to introducing the composition into the body of the mammal by any method established in the art. The composition being introduced is the "transplant", and the mammal is the "recipient". The transplant and the recipient may be syngeneic, allogeneic or xenogeneic. Preferably, the transplantation is an autologous transplantation.

An "effective amount" is an amount of a therapeutic agent sufficient to achieve the intended purpose. For example, an effective amount of a prolactin to increase the number of neural stem cells is an amount sufficient, *in vivo* or *in vitro*, as the case may be, to result in an increase in neural stem cell number. An effective amount of a prolactin to treat or ameliorate a neurodegenerative disease or condition is an amount of the prolactin sufficient to reduce or remove the symptoms of the neurodegenerative disease or condition. The effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration. The effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.

Methods

In an attempt to assess the effects of pregnancy-associated hormonal/physiological changes on the brain, we discovered that the number of neural stem cells (NSCs) increases during pregnancy in a two-wave pattern. Thus, NSC numbers increased in a detectable manner at gestational day 7, reached a maximum of 40% increase at gestational day 14 and

returned to baseline at birth. Surprisingly, a second increase occurred after birth, during the first post-natal week. The number of proliferating cells in the subventricular zone where neural stem cells are primarily located also increased during pregnancy in a two-wave pattern: doubled at gestational day 7, returned to baseline at gestational day 14, and followed by a second increase at birth (Example 1).

This two-wave pattern is similar to the pattern of prolactin levels in the same period of time. Prolactin concentrations are high during the first half of pregnancy, then decrease until the end of pregnancy when they rise again, presumably due to its role in lactation and maternal behaviors (reviewed in Freeman et al., 2000). Therefore, we investigated the effects of prolactin in neural stem cell number *in vivo* and *in vitro* (Examples 2 and 4). We found that prolactin is capable of inducing proliferation in the subventricular zone *in vivo* and increasing neural stem cell number *in vitro*.

In mammals, adult neural stem cells in the forebrain subventricular zone give rise to olfactory interneurons by forming neuronal progenitors that migrate along the rostral migratory stream to the olfactory bulb. Therefore, we also investigated whether pregnancy or prolactin-induced increase in neural stem cells results in olfactory interneuron formation. Indeed, the numbers of new olfactory interneurons in pregnant mice are significantly higher than those in their virgin counterparts. Moreover, after each of the two waves of neural stem cell increase, there is an increase in olfactory interneurons. Similarly, prolactin infusions led to significant increases in the number of new olfactory interneurons as well (Example 3).

The effect of prolactin and pregnancy on neurogenesis (about a 100% increase) is larger than that on stem cell proliferation (about 40-60%). Therefore, we determined whether prolactin is capable of promoting the differentiation of neural stem cells to neurons. To this end, neurospheres were cultured in the presence of EGF or EGF plus prolactin, and the numbers of neurons were counted (Example 5). The results indicate that neurospheres generated in the presence of both EGF and prolactin produced twice as many neurons as those generated in EGF alone. Accordingly, in addition to increasing proliferation of neural

stem cells and new olfactory neuron production, prolactin also enhances neuron formation from neural stem cells.

5 The effects of prolactin on neural stem cells may be exerted directly or indirectly. *In vivo*, prolactin receptors were previously reported to reside in the choroid plexus of the forebrain lateral ventricles. Since the choroid plexus secretes growth factors that regulate neural stem cell proliferation, such as transforming growth factor alpha (TGF), prolactin may stimulate the choroid plexus to secrete TGF, thereby inducing neural stem cells to proliferate. We discovered that prolactin receptors are also expressed in the dorsolateral corner of the SVZ, where neuronal progenitors depart for their migration along the rostral migratory stream to the olfactory bulb. Therefore, prolactin may also act on neural stem cells directly. Cultured neural stem cells were also found to have prolactin receptors.

15 Accordingly, the present invention provides a method of increasing neural stem cell numbers either *in vivo* or *in vitro*. When used to increase neural stem cell number *in vivo*, this method will result in a larger pool of neural stem cells in the brain. This larger pool of neural stem cells can subsequently generate more neural cells, particularly neurons or glial cells, than would a population of stem cells without prolactin. The neural cells, in turn, can compensate for lost or degenerate neural cells which are associated with neurodegenerative diseases and conditions, including nervous system injuries.

25 Prolactin can also be used to increase neural stem cell numbers *in vitro*. The resulting stem cells can be used to produce more neurons and/or glial cells *in vitro*, or used in transplantation procedures into humans or animals suffering from neurodegenerative diseases or conditions. It is preferable that neural stem cells produced according to the present invention, rather than neurons or glial cells, are transplanted. Once neural stem cells are transplanted, growth and/or differentiation factors can be administered *in vivo* to further increase the number of stem cells, or to selectively enhance neuron formation or glial cell formation. For example, we have found that erythropoietin induces selective production of neurons over glial cells. Cyclic AMP and factors which enhance the cAMP pathway, such as pituitary adenylate cyclase activating polypeptide (PACAP) and serotonin, are also good

candidates for selectively promoting neuron production. On the other hand, bone morphogenetic protein (BMP) has been reported to inhibit neuron production and enhance glial production by adult SVZ cells (Lim et al., 2000). Factors that can increase neural stem cell number include, without being limited to, prolactin, epidermal growth factor (EGF),
5 transforming growth factor alpha (TGF), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and ciliary neurotrophic factor (CNTF).

Further provided by the present invention are methods of increasing neuron formation from neural stem cells *in vitro* or *in vivo*, as well as methods of enhancing new olfactory
10 neuron production.

The increase in neural stem cells, neurons or olfactory interneurons is preferably at least about 10%, more preferably at least about 20%, even more preferably at least about 30%, yet more preferably at least about 40%, still more preferably at least about 50%, and
15 further more preferably at least about 60%. Most preferably, the increase is at least about 80%.

The present invention also provides a method for treating or ameliorating a neurodegenerative disease or condition in an animal, particularly a mammal. This can be achieved, for example, by administering an effective amount of a prolactin to the brain of the
20 mammal, or transplanting to the mammal neural stem cells, progenitor cells derived from neural stem cells, neurons and/or glial cells produced according to the present invention. Preferably, neural stem cells are transplanted. In addition to the transplantation, prolactin and/or additional factors can be further provided to the transplantation recipient, particularly concurrently with or after the transplantation.

25 One particularly interesting neurodegenerative condition is aging. We have found that the number of neural stem cells in the subventricular zone is significantly reduced in aged mice. Accordingly, it will be of particular interest to ameliorate problems associated with aging by increasing neural stem cell numbers with prolactin.

For example, the neural stem cell in the subventricular zone is the source of olfactory neurons, and olfactory dysfunction is a hallmark of forebrain neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's diseases. Disruption of neuronal migration to the olfactory bulb leads to deficits in olfactory discrimination, and doubling the new olfactory interneurons enhances new odor memory (Rocheffort et al., 2002). Therefore, prolactin can be used to enhance olfactory discrimination or olfactory memory, as well as physiological functions that are associated with olfaction and olfactory discrimination, such as mating, offspring recognition and rearing. In addition, any other methods that result in an increase in neural stem cell number, particularly in the SVZ, will lead to elevated new olfactory neuron formation, thereby enhancing olfactory functions.

Another particularly important application of the present invention is the treatment and/or amelioration of brain injuries, such as stroke. As shown in Example 6, prolactin increased neurogenesis in the brain of animals that suffered from a chemically induced stroke. Furthermore, these animals also showed significant improvement in a motor-related symptom, demonstrating the effect of prolactin in the treatment of brain injuries. When prolactin and erythropoietin were combined in this treatment, the animals recovered completely behaviorally, and the cavities in the motor cortex, which resulted from the injury, were also completely or partially filled up by cells and tissues.

Therefore, prolactin can be used to treat or ameliorate neurodegenerative diseases or conditions, particularly brain injuries, and most particularly stroke. Preferably, prolactin, and/or any other methods of increasing neural stem cells, can be used in conjunction with an additional factor that enhances neurogenesis and/or glial formation. Prolactin and erythropoietin are a particularly preferred combination in the present invention. In addition, prolactin and EGF, as well as prolactin and PACAP, are also preferred embodiments.

Compositions

The present invention provides compositions that comprises a prolactin and at least one additional factor. The additional factor is capable of increasing neural stem cell number

or enhancing neural stem cell differentiation to neurons or glial cells. The additional factor is preferably erythropoietin, EGF and/or PACAP.

Prolactin is a polypeptide hormone initially named for its activity to promote
5 lactation. However, it is now known that prolactin has over 300 different biological activities not represented by its name (Freeman et al., 2000). Furthermore, although it is long believed that prolactin is synthesized in and secreted from specialized cells (the lactotrophs) of the anterior pituitary gland only, there is increasing evidence suggesting that other organs and tissues in the body can make prolactin as well.

10 The brain is among the organs reported to contain, and probably synthesize, prolactin. Prolactin immunoreactivity was first found in hypothalamic axon terminals, and subsequently found in the telencephalon in the cerebral cortex, hippocampus, amygdala, septum, caudate putamen, brain stem, cerebellum, spinal cord, choroid plexi, and the circumventricular
15 organs. Known effects of prolactin on the central nervous system (CNS) include actions on maternal behavior, sexual behavior, grooming behavior, feeding behavior, sleep-wake cycle, the firing rate of hypothalamic neurons, and the metabolism of neurotransmitters and neuropeptides. Prolactin was also found to induce proliferation of astrocytes as well as astrocytic TGF expression (DeVito et al., 1995). However, this is the first time prolactin is
20 found to have an impact on neural stem cells.

In the human genome, a single gene encodes prolactin. The prolactin gene, found on chromosome 6, is 10 kb in size and contains 5 exons and 4 introns. Transcription of the prolactin gene is regulated by two independent promoter regions. The proximal 5 kb region
25 directs pituitary-specific expression, while a more upstream promoter region is responsible for extrapituitary expression. The gene codes for a 227 amino acid prolactin prohormone, which is processed to the 199 amino acid mature human prolactin.

Although the major form of prolactin found in the pituitary gland has a molecular
30 weight of 23 kDa, variants of prolactin have been characterized in many mammals, including humans. Prolactin variants can result from alternative splicing of the primary transcript,

proteolytic cleavage and other post-translational modifications. A prolactin variant of 137 amino acids has been described in the anterior pituitary, which is likely to be a product of alternative splicing. A variety of proteolytic products of prolactin have been characterized, particularly the 14-, 16- and 22-kDa prolactin variants, all of which appear to be prolactin fragments truncated at the C-terminus. Other post-translational modification reported for prolactin include dimerization, polymerization, phosphorylation, glycosylation, sulfation and deamidation.

The prolactin useful in the present invention includes any prolactin analog, variant or prolactin-related protein which is capable of increasing neural stem cell number. A prolactin analog or variant is a polypeptide which contains at least about 30% of the amino acid sequence of the native human prolactin, and which possesses a biological activity of prolactin. Preferably, the biological activity of prolactin is the ability to bind prolactin receptors. Although several isoforms of the prolactin receptor have been isolated, for example the long, intermediate and short forms in rat, the isoforms share the same extracellular domain which binds prolactin. Therefore, any receptor isoform can be used to assay for prolactin binding activity. Specifically included as prolactins are the naturally occurring prolactin variants, prolactin-related protein, placental lactogens, S179D-human prolactin (Bernichtein et al., 2001), prolactins from various mammalian species, including but not limited to, human, other primates, rat, mouse, sheep, pig, and cattle, and the prolactin mutants described in U.S. Patent Nos. 6,429,186 and 5,955,346.

Similarly, any additional compounds or factors that are useful in the present invention include their analogs and variants that share a substantial similarity and at least one biological activity with the native compounds or factors. For example, EGF can be used in conjunction with prolactin in the present invention. In addition to native EGF, an EGF analog or variant can also be used, which should share a substantial amino acid sequence similarity with the native EGF, as well as at least one biological activity with the native EGF, such as binding to the EGF receptor. Particularly included as an EGF is the native EGF of any species, TGF, or recombinant modified EGF. Specific examples include, but are not limited to, the recombinant modified EGF having a deletion of the two C-terminal amino acids and a neutral

amino acid substitution at position 51 (particularly EGF51gln51; U.S. Patent Application Publication No. 20020098178A1), the EGF mutein (EGF-X₁₆) in which the His residue at position 16 is replaced with a neutral or acidic amino acid (U.S. Patent No. 6,191,106), the 52-amino acid deletion mutant of EGF which lacks the amino terminal residue of the native EGF (EGF-D), the EGF deletion mutant in which the N-terminal residue as well as the two C-terminal residues (Arg-Leu) are deleted (EGF-B), the EGF-D in which the Met residue at position 21 is oxidized (EGF-C), the EGF-B in which the Met residue at position 21 is oxidized (EGF-A), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, amphiregulin, neuregulin, or a fusion protein comprising any of the above. Other useful EGF analogs or variants are described in U.S. Patent Application Publication No. 20020098178A1, and U.S. Patent Nos. 6,191,106 and 5,547,935.

As another example, PACAP can also be used in conjunction with prolactin. Useful PACAP analogs and variants include, without being limited to, the 38 amino acid and the 27 amino acid variants of PACAP (PACAP38 and PACAP27, respectively), and the analogs and variants disclosed in, *e.g.*, U.S. Patent Nos. 5,128,242; 5,198,542; 5,208,320; 5,326,860; 5,623,050; 5,801,147 and 6,242,563.

Erythropoietin analogs and variants are disclosed, for example, in U.S. Patent Nos. 6,048,971 and 5,614,184.

Further contemplated in the present invention are functional agonists of prolactin or additional factors useful in the present invention. These functional agonists bind to and activate the receptor of the native factor, although they do not necessarily share a substantial sequence similarity with the native factor. For example, maxadilan is a polypeptide that acts as a specific agonist of the PACAP type-1 receptor (Moro et al., 1997).

Functional agonists of EPO have been extensively studied. EMP1 (EPO mimetic peptide 1) is one of the EPO mimetics described in Johnson et al., 2000. Short peptide mimetics of EPO are described in, *e.g.*, Wrighton et al., 1996 and U.S. Patent No. 5,773,569. Small molecular EPO mimetics are disclosed in, *e.g.*, Kaushansky, 2001. Antibodies that

activate the EPO receptor are described in, *e.g.*, U.S. Patent No. 5,885,574; WO 96/40231 and WO 97/48729).

Antibodies that have agonist activities for the EGF receptor are described, *e.g.*, in
5 Fernandez-Pol, 1985 and U.S. Patent No. 5,723,115. In addition, activating amino acid
sequences are also disclosed in U.S. Patent No. 6,333,031 for the EPO receptor, EGF
receptor, prolactin receptor and many other cell surface receptors; metal complexed receptor
ligands with agonist activities for the prolactin and EPO receptors can be found in U.S. Patent
No. 6,413,952. Other methods of identifying and preparing ligands for receptors, *e.g.*, EPO
10 and prolactin receptors, are described, for example, in U.S. Patent Nos. 5,506,107 and
5,837,460.

It should be noted that the effective amount of each analog, variant or functional
agonist may be different from that for the native factor or compound, and the effective
15 amount in each case can be determined by a person of ordinary skill in the art according to
the disclosure herein. Preferably, the native factors, or analogs and variants that share
substantial sequence similarity with the native factors, are used in the present invention.

Pharmaceutical compositions are also provided, comprising a prolactin, an additional
20 factor as described above, and a pharmaceutically acceptable excipient and/or carrier.

The pharmaceutical compositions can be delivered via any route known in the art,
such as parenterally, intrathecally, intravascularly, intravenously, intramuscularly,
transdermally, intradermally, subcutaneously, intranasally, topically, orally, rectally,
25 vaginally, pulmonarily or intraperitoneally. Preferably, the composition is delivered into the
central nervous system by injection or infusion. More preferably it is delivered into a
ventricle of the brain, particularly the lateral ventricle. Alternatively, the composition is
preferably delivered by systemic routes, such as subcutaneous administration. For example,
we have discovered that prolactin, growth hormone, IGF-1, PACAP and EPO can be
30 effectively delivered by subcutaneous administration to modulate the number of neural stem
cells in the subventricular zone.

When the composition is not directly delivered into the brain, and factors in the composition do not readily cross the blood brain barrier, a blood brain barrier permeabilizer can be optionally included to facilitate entry into the brain. Blood brain barrier permeabilizers are known in the art and include, by way of example, bradykinin and the bradykinin agonists described in U.S. Patent Nos. 5,686,416; 5,506,206 and 5,268,164 (such as NH_2 -arginine-proline-hydroxyproline-glycine-thienylalanine-serine-proline-4-Me-tyrosine- \square (CH_2NH)- arginine-COOH). Alternatively, the factors can be conjugated to the transferrin receptor antibodies as described in U.S. Patent Nos. 6,329,508; 6,015,555; 5,833,988 or 5,527,527. The factors can also be delivered as a fusion protein comprising the factor and a ligand that is reactive with a brain capillary endothelial cell receptor, such as the transferrin receptor (see, *e.g.*, U.S. Patent No. 5,977,307).

The pharmaceutical compositions can be prepared by mixing the desired therapeutic agents with an appropriate vehicle suitable for the intended route of administration. In making the pharmaceutical compositions of this invention, the therapeutic agents are usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the pharmaceutically acceptable excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the therapeutic agent. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the therapeutic agents, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable excipients include artificial cerebral spinal fluid, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-

benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the therapeutic agents after administration to the patient by employing procedures known in the art.

5 For preparing solid compositions such as tablets, the therapeutic agent is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the therapeutic agents are dispersed evenly throughout the composition so that the composition may be readily
10 subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

 The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in
15 the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose
20 acetate.

 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as
25 corn oil, cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
30 The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein. The compositions are administered by the oral or nasal respiratory route

for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder
5 compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

Another formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide
10 continuous or discontinuous infusion of the therapeutic agent of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, for example, U.S. Patent 5,023,252, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

15

Other suitable formulations for use in the present invention can be found in *Remington's Pharmaceutical Sciences*.

The following examples are offered to illustrate this invention and are not to be
20 construed in any way as limiting the scope of the present invention.

EXAMPLES

In the examples below, the following abbreviations have the following meanings. Abbreviations not defined have their generally accepted meanings.

25

$^{\circ}\text{C}$	=	degree Celsius
hr	=	hour
min	=	minute
μM	=	micromolar
30 mM	=	millimolar
M	=	molar

	ml	=	milliliter
	μ l	=	microliter
	mg	=	milligram
	μ g	=	microgram
5	FBS	=	fetal bovine serum
	PBS	=	phosphate buffered saline
	DMEM	=	Dulbecco's modified Eagle's medium
	α -MEM	=	α -modified Eagle's medium
	EGF	=	epidermal growth factor
10	NSC	=	neural stem cell
	SVZ	=	subventricular zone
	PACAP	=	pituitary adenylate cyclase activating polypeptide
	cAMP	=	cyclic AMP
	BMP	=	bone morphogenetic protein
15	CSF	=	cerebral spinal fluid

Materials and Methods

Neural stem cell culture

20 The protocols for neural stem cell culture are described in detail in U.S. Patent No. 5,750,376 or Shingo et al., 2001. Briefly, embryonic neural stem cells were prepared from E14 medial and lateral ganglionic eminences. Adult neural stem cells were prepared from the subventricular zone of adult mice. The tissue was cultured in basal medium containing 20 ng/ml EGF, or other growth factors as indicated in each case, to form neurospheres. The
25 composition of the basal medium is as follows: DMEM/F12 (1:1); glucose (0.6%); glutamine (2 mM); sodium bicarbonate (3 mM); HEPES (5 mM); insulin (25 μ g/ml); transferrin (100 μ g/ml); progesterone (20 nM); putrescine (60 μ M); and selenium chloride (30 nM).

30 Seven days later, the neurospheres (primary neurospheres) were passaged by mechanical dissociation and reseeded as single cells (passage 1). For secondary

neurospheres, the single cells were then cultured for seven days to form secondary neurospheres.

Test animals for the stroke study

5 Adult male Long-Evans rats (250-350g) were obtained from Charles River Breeding Farms (Laval, Quebec, Canada) and were adapted to the colony for two weeks prior to any treatment. A week before surgery the rats were given a baseline testing on the forelimb inhibition test.

10 *Focal ischemic injury and infusion*

 The animals for the stroke study received unilateral devascularization of the sensorimotor cortex. Using Isoflurane anesthesia, the skin was incised and retracted and the overlying fascia were removed from the skull. A skull opening was made at the following coordinates, taking care not to damage the dura: AP +4.0 to -2.0; L 1.5 to 4 (the parasagittal
15 ridge; Kolb et al., 1997). The dura was cut and retracted from the skull opening. A cotton swab soaked in sterile saline was gently rubbed across the exposed pia and the vessels were removed. A hole was then drilled in the contralateral hemisphere to provide an opening for the cannulae attached to the osmotic minipump at AP-.5; L 1.5. An osmotic minipump was placed under the skin between the shoulder blades and a tube connected under the skin to the
20 cannulae, which was attached to the skull with fast-drying cement. Once hemostasis had been achieved the scalp was sutured closed with 5-O sterile suture. The animals were given a single injection of Banamine (an analgesic) and returned to their home cage. Sham animals received only anesthesia, the bone opening, and the skin was incised and sutured.

25 Six days later the animals were assessed using the behavioral test and on the following day the animals were re-anesthetized and the minipump was replaced with a second one containing the appropriate solutions. Sham animals were only anesthetized. The animals were retested 7, 14, and 28 days later to yield behavioral measures on weeks 1,2,3,4, and 6.

30

Forelimb inhibition test

This test has been shown to constitute a sensitive measure of functional integrity of regions of anterior neocortex. In normal rats, swimming is accomplished by propulsion from the hind limbs. The forelimbs are normally inhibited from any stroking and are held
5 immobile and together under the animal's neck. Inhibition of the forelimbs was assessed by filming animals while swimming. The animals were introduced into one end of an aquarium (30 w x 90 l x 43 h cm) filled to a depth of 25 cm with room temperature water (~25°C) and filmed as they swim to a 9.5 cm square visible platform. This platform projects 2 cm above the surface of the water and is positioned at the opposite end of the aquarium. Scoring of
10 inhibition was done by counting the number of strokes, if any, made by each forelimb in three swims along the length of the aquarium. A swim was deemed scorable only if the animal did not touch the sides of the aquarium during the swimming trial.

Brain anatomical analysis

15 At the conclusion of week 6 the animals were given an overdose of Euthanol and intracardially perfused with 0.9% saline and 4% paraformaldehyde in picric acid. The brains were cryoprotected and cut on a Vibratome at 40 microns. Five sets of sections were kept every 400 microns. Two sets were stained, one with Cresyl Violet and one with Doublecortin. The remaining sets were saved. The Cresyl Violet staining was performed on
20 the slides whereas the Doublecortin was performed as an immunohistochemical procedure on free-floating sections. The Cresyl Violet staining allows assessment of lesion extent whereas the Doublecortin stains for a microtubule associated protein that is present in migrating neuronal progenitor cells.

25 EXAMPLE 1 Neural Stem Cell Number Increases During Pregnancy

The numbers of neural stem cells in the forebrain of adult CD1 mice were determined in pregnant mice (6-8 weeks old) and age-matched virgin mice in order to investigate the effect of pregnancy. The entire subventricular zones of the forebrain (both hemispheres) of
30 adult female mice were collected at various points during pregnancy, dissected, enzymatically dissociated and plated in defined culture medium in the presence of epidermal

growth factor as described in U.S. Patent No. 5,750,376. These cells were allowed to develop into primary neurospheres. Seven to ten days later, the numbers of neurospheres, each of which is clonally derived from a single stem cell, were counted.

5 In parallel experiments, numbers of proliferating cells in subventricular zones of mice during pregnancy were also assessed. The mice were labeled with bromodeoxyuridine (BrdU), and sections of subventricular zones were subjected to immunoassays with BrdU specific antibodies.

10 The results of both measurements are shown in Figure 1. In the forebrain of pregnant mice, NSC numbers increased transiently: first detectable at gestational day 7, reaching a maximum at gestational day 14 (40% increase) and returned to baseline at birth. Surprisingly, a second increase occurred after birth, during the first post-natal week. The number of BrdU immunoreactive cells also increased during pregnancy in a similar pattern
15 which preceded the increases in NSC numbers: increased by 65% at gestational day 7, and returned to baseline at gestational day 14. At birth, a second increase (35%) in BrdU immunoreactive cells was observed. Therefore, both NSC number and proliferation in the subventricular zone increase in two waves during pregnancy and/or post-natal period.

20

EXAMPLE 2 Prolactin Effect *in vivo*

 The two-wave pattern of NSC number increase during pregnancy and/or post-natal period described in Example 1 is similar to the pattern of prolactin levels in the same period
25 of time. Prolactin concentrations are high during the first half of pregnancy, then decrease until the end of pregnancy when they rise again, presumably due to its role in lactation and maternal behaviors (reviewed in Freeman et al., 2000). Although prolactin was first identified as a reproductive hormone, it has then become clear that its functions are highly diverse. The effects of prolactin on the central nervous system (CNS) include actions on
30 maternal behavior, sexual behavior, grooming behavior, feeding behavior, sleep-wake cycle,

the firing rate of hypothalamic neurons, and the metabolism of neurotransmitters and neuropeptides.

To determine if prolactin is capable of increasing NSC numbers, we infused prolactin
5 into 6-8 week old ovariectomized mice either subcutaneously (SC, 8 μ g/day for six days) or
intracerebroventricularly (ICV, 0.8 μ g/day for six days. BrdU was infused at the same time
into the brain to assess proliferative activity in the brain. 6 days later, the number of BrdU
immunoreactive cells were determined with BrdU specific antibodies. The results show that
10 infusion of prolactin increased BrdU-labeled cells in the forebrain SVZ via both routes (an
increase of 53% for SC and 61% for ICV; Figure 2A). Therefore, prolactin can simulate cell
proliferation in the subventricular zone, a main location of NSC in adult mice.

We further compared the response to prolactin in female and male animals, and the
results are shown in Figure 2C. Infusion of either prolactin (0.8 μ g/day for six days) or
15 prolactin releasing peptide (9 pg/day for six days) into the lateral ventricles increased
proliferation in the forebrain SVZ in 6-8 week old male mice by 57% and 38%, respectively.
These increases were comparable, albeit to a lesser extent, to those seen in age-matched non-
ovariectomized females (74% and 56%, respectively). Therefore, prolactin can stimulate
neural stem cell proliferation in both male and female animals.

20

EXAMPLE 3 The Effects of pregnancy and prolactin on olfactory neurons

Since the SVZ neural stem cells are the source of ongoing neurogenesis in the
olfactory bulb, we investigated if the effects of pregnancy and prolactin on neural stem cells
25 are also reflected in olfactory neurogenesis. Virgin or age-matched pregnant 6-8 week old
CD1 mice were injected with bromodeoxyuridine (BrdU) to label mitotic cells as in Example
1 on gestation day 7 or postpartum day 7. Four weeks after the BrdU injection, the number
of BrdU labeled cells in various parts of the brain were counted. The pregnant mice that
were injected on gestation day 7 had significantly more BrdU-labeled cells in both the
30 granule and dopaminergic periglomerular cell layers of the olfactory bulb than their virgin
counterparts. These results are consistent with the observation that pregnancy increases

neural stem cells in the subventricular zone, which are known to form neuronal progenitor cells that migrate to the olfactory bulb.

5 Since the dopaminergic periglomerular layer of the olfactory bulb represents a homogeneous neuronal population, we then focused on this layer and counted the numbers of BrdU-labeled tyrosine hydroxylase-immunoreactive periglomerular neurons. Two or four weeks after BrdU injections, the pregnant mice labeled on both gestation day 7 and postpartum day 7 had 50-100% more new periglomerular neurons than the virgin controls. Therefore, each of the two waves of SVZ neural stem cell proliferation, in the gestation and postpartum stages, respectively, results in a doubling of new olfactory bulb interneuron formation.

We also determined whether neurogenesis in the olfactory bulb observed in pregnant mice was also stimulated by prolactin. Adult mice were infused with prolactin as described in Example 2, and the numbers of new olfactory interneurons were determined. The results show that new olfactory interneuron number doubled four weeks after prolactin infusion (Figure 2B), indicating that prolactin infusions have the same effect on neurogenesis as pregnancy does, and prolactin is the maternal factor to mediate this physiological process.

20 **EXAMPLE 4 Prolactin Effect *in vitro***

To determine the effect of prolactin on cultured neural stem cells, primary stem cell cultures were prepared as described in Materials and Methods. The cells were incubated for 7 days in the presence of EGF alone, or EGF plus prolactin, in addition to basal media. The number of the resulting neurospheres (primary neurospheres) were counted, and the neurospheres were dissociated to allow formation of secondary neurospheres. While prolactin alone did not significantly increase the number of neurospheres *in vitro* (data not shown), the results indicate that prolactin is capable of potentiating the effect of EGF to increase neurospheres (Figure 3). Furthermore, the ability of primary neurospheres to generate secondary neurospheres was also increased by 25% in the presence of prolactin (Figure 3). This is the first time prolactin is shown to act on neural stem cells.

EXAMPLE 5 Prolactin enhances neuronal differentiation

Neurospheres were cultured, as described in Example 4, in the presence of EGF alone
5 or EGF plus 30 nM prolactin. Seven days later, the neurospheres were allowed to
differentiate in basal media only, the numbers of neurons were determined by
immunostaining for α -tubulin, counted, and expressed as percentages of total cells. As shown
in Figure 4, the percentage of neurons was twice as much when prolactin was included to
grow neurospheres. Therefore, prolactin is capable of enhancing neuron formation from
10 neural stem cells.

EXAMPLE 6 The effect of prolactin in a stroke model

In order to determine the effect of prolactin administration in animals that suffer a
15 brain injury, focal ischemic injuries were introduced into the brains of rats as a model of
stroke. As a result of the brain injury, the animals had lesions in the motor cortex and
behaved abnormally in the forelimb inhibition test, which is a sensitive measure of functional
integrity of regions of the anterior neocortex. The animals then received various test factors,
and the effects of these factors on the forelimb inhibition test and brain anatomy were
20 assessed. As controls, a sham control group received a sham brain injury and no test factors,
and a vehicle control group received the brain injury as well as infusions of artificial cerebral
spinal fluid (CSF). The treatments each test group received are summarized below:

Group	Brain Injury	First Infusion (days 1-7)	Second Infusion (days 8-14)
1	sham	none	none
2	yes	CSF	CSF
3	yes	prolactin	CSF
4	yes	prolactin	erythropoietin (EPO)

25 The schedule and procedure of the brain injury, infusion, behavioral test and
anatomical analysis are described in Materials and Methods.

Before the brain injury, all rats inhibited both forepaws in the forelimb inhibition test, which is expected from normal rats. After the injury, all ischemic groups (Groups 2-4) failed to inhibit the contralateral forepaw, but they continued to inhibit the ipsilateral forepaw.

5 Upon infusion of the test factors, the two prolactin groups (Groups 3 and 4) showed greater forepaw inhibition. In fact, by the end of the last week (4 weeks after completion of the infusions), the prolactin plus EPO group (Group 4) was indistinguishable from the controls. Therefore, prolactin, and particularly the combination of prolactin and EPO, resulted in a recovery from a representative symptom of stroke.

10 Anatomically, the prolactin group showed a high degree of doublecortin staining in the brain, indicating that prolactin induced extensive neurogenesis. The rats in the prolactin plus EPO group had an expanded subventricular zone, indicating a significant cell increase in this area. In addition, many doublecortin positive cells appeared in the lesioned area, white
15 matter and the lateral ventricle. A stream of doublecortin positive cells could be observed between the subventricular zone and the lesioned area. Since doublecortin is a marker of migrating neuronal progenitor cells, these results indicate that neural stem cells gave rise to neuronal progenitor cells upon treatment, and the progenitor cells migrated to the lesioned area. The new growth in the lesioned area was so extensive that the cavities created by the
20 ischemic injury were completely or partially filled up in a majority of the rats in this group. These anatomical results thus strongly support the behavioral study that prolactin, or the combination of prolactin and EPO, can be used to treat brain injuries such as stroke.

We claim:

1. A method of increasing neural stem cell number, comprising providing an effective amount of a prolactin to at least one neural stem cell under conditions which result in an increase in the number of neural stem cells.
2. The method of claim 1 wherein the neural stem cell is located in the brain of a mammal.
3. The method of claim 2 wherein the neural stem cell is located in the subventricular zone of the brain.
4. The method of claim 3 wherein the prolactin is administered to the ventricle of the brain.
5. The method of claim 2 wherein the mammal is an adult mammal.
6. The method of claim 2 wherein the mammal suffers from or is suspected of having a neurodegenerative disease or condition.
7. The method of claim 1 wherein the neural stem cell is cultured *in vitro*.
8. The method of claim 1 further comprising providing at least one additional factor to the neural stem cell.
9. The method of claim 8 wherein the additional factor is selected from the group consisting of erythropoietin, cyclic AMP, pituitary adenylate cyclase activating polypeptide (PACAP), serotonin, bone morphogenetic protein (BMP), epidermal growth factor (EGF), transforming growth factor alpha (TGF), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and ciliary neurotrophic factor (CNTF).

10. A method of treating or ameliorating a neurodegenerative disease or condition in a mammal, comprising providing an effective amount of a prolactin to the mammal.
- 5 11. The method of claim 10 wherein the disease or condition is a brain injury.
12. The method of claim 11 wherein the brain injury is a stroke.
13. The method of claim 11 wherein the brain injury is associated with brain surgery.
- 10 14. The method of claim 10 wherein the neurodegenerative disease or condition is selected from the group consisting of Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease.
- 15 15. The method of claim 10 wherein the mammal receives a transplantation of neural stem cells and/or neural stem cell progeny prior to or concurrently with the prolactin.
16. The method of claim 10 further comprising providing at least one additional factor to the mammal.
- 20 17. The method of claim 16 wherein the additional factor is selected from the group consisting of erythropoietin, cyclic AMP, pituitary adenylate cyclase activating polypeptide (PACAP), serotonin, bone morphogenetic protein (BMP), epidermal growth factor (EGF), transforming growth factor alpha (TGF), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and ciliary neurotrophic factor (CNTF).
- 25 18. The method of claim 10 wherein the prolactin is provided by administering the prolactin intravascularly, intrathecally, intravenously, intramuscularly, subcutaneously, intraperitoneally, topically, orally, rectally, vaginally, nasally, by
- 30 inhalation or into the brain.

19. The method of claim 10 wherein the prolactin is administered subcutaneously.
20. The method of claim 10 wherein the prolactin is provided by administering to the
5 mammal an effective amount of a prolactin-inducing agent.
21. The method of claim 20 wherein the prolactin-inducing agent is prolactin releasing peptide.
- 10 22. A method of enhancing neuron formation from neural stem cells, comprising providing a prolactin to at least one neural stem cell under conditions that result in enhanced neuron formation from said neural stem cell.
23. The method of claim 22 wherein the neural stem cell is located in the brain of a
15 mammal.
24. The method of claim 23 wherein the neural stem cell is located in the subventricular zone of the brain.
- 20 25. The method of claim 23 wherein the prolactin is administered to the ventricle of the brain.
26. The method of claim 23 wherein the mammal is an adult mammal.
- 25 27. The method of claim 22 wherein the neural stem cell is cultured *in vitro*.
28. The method of claim 22 further comprising providing at least one additional factor to the neural stem cell.
- 30 29. The method of claim 28 wherein the additional factor is selected from the group consisting of erythropoietin, cyclic AMP, pituitary adenylate cyclase activating

polypeptide (PACAP), serotonin, epidermal growth factor (EGF), transforming growth factor alpha (TGF α), fibroblast growth factor (FGF), estrogen, growth hormone, insulin-like growth factor 1, and ciliary neurotrophic factor (CNTF).

- 5 30. A method of increasing new neuron formation in the olfactory bulb of a mammal, comprising providing an effective amount of a prolactin to the mammal.

1/4




FIGURE 1

2/4




FIGURE 2

3/4





FIGURE 3

4/4

**FIGURE 4**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/024472 A3

(51) International Patent Classification⁷: C12N 5/06,
5/08, A61K 38/22, 38/27, 38/30, 35/30, A61P 25/00 //
(A61K 38/27, 38:22) (A61K 38/22, 38:18) (A61K 38/22,
31:565) (A61K 38/30, 38:22)

(21) International Application Number: PCT/CA02/01345

(22) International Filing Date: 30 August 2002 (30.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/322,514 14 September 2001 (14.09.2001) US
60/386,404 7 June 2002 (07.06.2002) US

(71) Applicant (for all designated States except US): **STEM CELL THERAPEUTICS INC.** [CA/CA]; Suite 240, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEISS, Samuel** [CA/CA]; 4540 Chapel Road, N.W., Calgary, Alberta T2L 1A6 (CA). **SHINGO, Tetsuro** [JP/JP]; 3-9-33 #103, Aoe, Okayama 700-0941 (JP).

(74) Agent: **TORYS LLP**; Suite 3000, 79 Wellington St. W., Box 270, TD Centre, Toronto, Ontario M5K 1N2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,

TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
18 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROLACTIN INDUCED INCREASE IN NEUTRAL STEM CELL NUMBERS AND THERAPEUTICAL USE THEREOF

(57) Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced *in vivo* to obtain more neural stem cells *in situ*, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced *in vitro* to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.

WO 03/024472 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 02/01345

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N5/06 C12N5/08 A61K38/22 A61K38/27 A61K38/30 A61K35/30 A61P25/00 //(A61K38/27,38:22),(A61K38/22,38:18), (A61K38/22,31:565),(A61K38/30,38:22) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, MEDLINE, BIOSIS, WPI Data, PAJ, CHEM ABS Data, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 13650 A (CLARK ROSS GRAHAM ; WILLIAMS CHRIS EDWARD (NZ); NEURONZ LIMITED (NZ) 16 March 2000 (2000-03-16) claim 11 page 3, line 15-18,20-25 page 5, line 17-22 page 18, line 19,22,23,33 page 19, line 3 --- -/--	1,2,4-6, 10,30 1-19, 22-30
Y		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *G* document member of the same patent family		
Date of the actual completion of the international search 30 June 2003		Date of mailing of the international search report - 9. 07. 2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Authorized officer Lechner, O

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 02/01345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>GAGE FRED H: "Mammalian neural stem cells." SCIENCE (WASHINGTON D C)., vol. 287, no. 5457, 25 February 2000 (2000-02-25), pages 1433-1438, XP002220467 ISSN: 0036-8075 abstract page 1435, left-hand column, paragraph 3 -middle column, paragraph 2 page 1437, right-hand column, paragraph 2 -page 1438, left-hand column, paragraph 3</p>	1-19, 22-30
Y	<p>PHELPS CAROL J ET AL: "Pituitary hormones as neurotrophic signals: Update on hypothalamic differentiation in genetic models of altered feedback." PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 222, no. 1, October 1999 (1999-10), pages 39-58, XP001109226 ISSN: 0037-9727 abstract -& PHELPS-CJ ET AL.: "Stimulatory effect of human, but not bovine, growth hormone expression on numbers of tuberoinfundibular dopaminergic neurons in transgenic mice" ENDOCRINOLOGY, vol. 138, no. 7, 1997, pages 2849-2855, XP002219915 abstract</p>	1-19, 22-30
Y	<p>WO 99 21966 A (NEUROSPHERES HOLDINGS LTD) 6 May 1999 (1999-05-06) page 5, line 19-25 page 6, line 19-30 claims 1-5</p>	1-19, 22-30
Y	<p>DICICCO-BLOOM E ET AL: "The PACAP ligand/receptor system regulates cerebral cortical neurogenesis." ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. UNITED STATES 11 DEC 1998, vol. 865, 11 December 1998 (1998-12-11), pages 274-289, XP001080359 ISSN: 0077-8923 abstract page 274, paragraph 1 page 275, last paragraph page 277, paragraph 1 page 282, paragraph 1 page 283, last paragraph page 287, paragraph 2</p>	1-19, 22-30

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 02/01345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LEE MATTHEW ET AL: "Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors." JOURNAL OF NEUROSCIENCE, vol. 21, no. 11, 1 June 2001 (2001-06-01), pages 3849-3859, XP002245598 ISSN: 0270-6474 abstract page 3849 -page 3850, left-hand column, paragraph 1 ---	1-19, 22-30
Y	WO 00 05260 A (SOD CONSEILS RECH APPLIC ;DONG ZHENG X (US)) 3 February 2000 (2000-02-03) abstract page 3, line 15-18 claims 19-22 -----	1-19, 22-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 02/01345

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-19, 22-30 (all as far as relating to in vivo methods) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-19, 22-30 (only partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-19, 22-30 (all partially, i.e. inventions 1, 2 and 4)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-7, 10-15, 18, 19, 22-27, 30

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using prolactin (PRL)

2. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and EPO

3. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and cAMP

4. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and PACAP

5. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and serotonin

6. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and BMP

7. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients suffering from neurodegenerative diseases, brain injuries etc. using PRL and EGF

8. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

suffering from neurodegenerative diseases, brain injuries
etc. using PRL and TGF-alpha

9. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL and FGF

10. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL and estrogen

11. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL and GH

12. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL and IGF-1

13. Claims: 8, 9, 16, 17, 28, 29 (all partially)

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL and CNTF

14. Claims: 20, 21

Method of increasing neuronal cells for treating patients
suffering from neurodegenerative diseases, brain injuries
etc. using PRL-releasing peptide

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-19, 22-30 (only partially)

Present claims 1-19, 22-30 relate according to the description (c.f. page 11, line 8-21) and the corresponding definitions of single terms and phrases such as "substantial sequence similarity" provided within the description, etc. to an extremely large number of molecules termed a prolactin.

Due to the broad definition provided, growth hormone (GH), being an agonist of the PRL-R is considered to fall within the definition of PRL.

Present claims 1-19, 22-30 relate to an extremely large number of pathologic conditions/diseases (as far as relating to in vivo methods) and methods, respectively, characterized by a result to be achieved and/or pathophysiological mechanism, i.e. increase in the number of neural stem cells, neurodegenerative disease or condition, brain injury (associated with brain surgery), increasing new neuron formation in the olfactory bulb. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the pathologic conditions/diseases claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the use of PRL alone or in combination with EPO or PACAP for in vitro use and for treating the specific diseases/ pathologic conditions mentioned on page 4, line 3-14 and page 13, line 22-28.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 02/01345

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0013650	A	16-03-2000	AU 757907 B2	13-03-2003
			AU 5885999 A	27-03-2000
			BR 9913457 A	16-10-2001
			CA 2343214 A1	16-03-2000
			CN 1316908 T	10-10-2001
			EP 1109572 A2	27-06-2001
			JP 2002524402 T	06-08-2002
			WO 0013650 A2	16-03-2000
			NZ 510253 A	28-02-2003
WO 9921966	A	06-05-1999	AU 9617398 A	17-05-1999
			CA 2307017 A1	06-05-1999
			WO 9921966 A1	06-05-1999
			JP 2001520878 T	06-11-2001
			US 2002094571 A1	18-07-2002
			US 2002098585 A1	25-07-2002
			US 6165783 A	26-12-2000
			US 2003104619 A1	05-06-2003
			US 2001039049 A1	08-11-2001
WO 0005260	A	03-02-2000	AU 3826899 A	14-02-2000
			CA 2335341 A1	03-02-2000
			CZ 20010253 A3	14-11-2001
			WO 0005260 A1	03-02-2000
			EP 1098906 A1	16-05-2001
			HU 0104934 A2	29-04-2002
			JP 2002521390 T	16-07-2002
			NO 20010284 A	19-03-2001
			PL 345583 A1	17-12-2001